Press Releases
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Boca Raton Regional Hospital
Kathy Schilling, MD, Boca Raton Regional Hospital, to discuss how ProFound AI helped nine dedicated breast radiologists find 23% more cancers, without increasing the rate of recalls NASHUA, N.H., April 25, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions,…
New and Real-World Clinical Evidence Confirms ProFound AI Increases Cancer Detection and Reveals Critical Clues to Inform Clinical Decisions
New research presented at American Roentgen Ray Society (ARRS) meeting continues to validate unique value iCAD’s deep-learning breast AI solution offers to clinicians and patients NASHUA, N.H., April 20, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today…
Cleveland Clinic Radiologist Presents Use Case of iCAD’s Breast AI Technology at Siemens Healthineers Innovations for Healthcare Professionals Education Symposium
Dr. Laura Dean to discuss how AI solutions minimizes interval cancers and helps clinicians overcome challenges associated with digital breast tomosynthesis Laura Dean, MD, a radiologist at the Cleveland Clinic, will discuss the use of iCAD’s Breast AI Suite for patients and clinicians in a presentation titled “Minimizing Interval…
iCAD Strengthens Leadership Team with Appointment of Chief Financial Officer and New Senior Executives
Eric Lonnqvist as Chief Financial Officer, Vasu Avadhanula as Chief Product Officer, and Michelle Strong as Chief Operations Officer bolster the Company’s executive leadership team and accelerate the Company’s growth strategies NASHUA, N.H., April 17, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer…
ProFound AI Risk Outperforms Traditional, Widely-Accepted Breast Cancer Risk Models for Both Short-term and Long-term Risk Assessments
ProFound AI Risk offered higher accuracy than Tyrer-Cuzick v8 for all women, regardless of menopausal status, breast density, and family history of breast cancer NASHUA, N.H., April 4, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new…
iCAD Reports Financial Results for Fourth Quarter ended December 31, 2022 and Year End
Strategy focused on profitability by end of 2024, using current cash on hand New leadership to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – March 28, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported…
iCAD’s Breast AI Suite Empowers Customers to Lead the Way in Support of FDA’s National Breast Density Reporting Standard
iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual Conference NASHUA, N.H., March 23, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its technologies are empowering customers to lead the way in…
iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023
Company is exploring strategic options for its Therapy business line NASHUA, N.H., March 13, 2023 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31,…
iCAD Announces Leadership Transition
Stacey Stevens Resigns as President and CEO and as a Member of the Board Dana Brown Named President and CEO, remains Chairman of the Board NASHUA, N.H. – March 13, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced…
New Real-World Clinical Evidence Confirms ProFound AI Boosts Radiologists’ Efficiency and Accuracy
Company’s Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at ECR 2023 NASHUA, N.H. – March 1, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world clinical evidence to…